Onyx Pharmaceuticals Initiates Phase 3 Myeloma Trial Of Carfilzomib – Onyx Pharmaceuticals on Wednesday announced the start of enrollment for an inter­na­tional Phase 3 trial of carfilzomib in re­lapsed/refractory multiple myeloma patients. The trial will enroll 700 patients and will test car­filz­o­mib in com­bi­na­tion with Revlimid (lena­lido­mide) and low-dose dexamethasone (Decadron) versus Revlimid and low-dose dexa­meth­a­sone without car­filz­o­mib. Carfilzomib is a proteasome inhibitor that prevents the growth and spread of myeloma cells by interrupting their protein-related cellular processes. For more in­­for­ma­tion, please see the Onyx Pharmaceuticals press release and the clinical trial description.

EntreMed’s ENMD-2076 Shows Anti-Myeloma Activity – EntreMed announced last week that its new cancer com­­pound ENMD-2076 showed significant anti-myeloma activity in pre-clinical studies. EntreMed has already launched a Phase 1 study in multiple myeloma patients. ENMD-2076 prevents the growth and spread of myeloma cells by interfering with cell division. For more in­­for­ma­tion, please see the EntreMed press release and the clinical trial description.

IMF Will Hold Myeloma Patient & Family Seminar – The Inter­na­tional Myeloma Foundation (IMF) will be holding a seminar for myeloma patients and their families August 13 to 14 in Philadelphia, PA. Myeloma experts Dr. Brian Durie and Dr. Robert Kyle are among the speakers scheduled to present during Saturday’s general session. The cost for the seminar is $60 per person. For more in­­for­ma­tion or to register, please visit the IMF website.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.